PrimeC Long-Term Survival Data to Be Presented at a Leading ALS Scientific Conference
MWN-AI** Summary
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) has announced the presentation of compelling long-term survival data from its Phase 2b PARADIGM trial of PrimeC at the upcoming Muscular Dystrophy Association (MDA) Clinical & Scientific Conference on March 9, 2026. The trial focused on patients with amyotrophic lateral sclerosis (ALS), a serious neurodegenerative disease that leads to paralysis and death within 2-5 years post-diagnosis.
The analysis employed a Cox proportional hazards model, revealing a statistically significant 65% reduction in the risk of death associated with PrimeC treatment (hazard ratio: 0.35; p=0.0037) after adjusting for baseline risk factors. Additionally, participants receiving PrimeC demonstrated a significant median survival increase of over 14 months—36.3 months compared to 21.4 months in the placebo group (log-rank p=0.0218). These findings reflect the drug's potential as a disease-modifying therapy for ALS and provide strong justification for continued development and regulatory engagement.
Dr. Jinsy Andrews, a noted ALS researcher and member of NeuroSense’s Scientific Advisory Board, will present the data, emphasizing the favorable safety profile alongside PrimeC's effects on iron metabolism and miRNA regulation in ALS. The PARADIGM trial included 68 ALS patients randomized to receive either PrimeC or a placebo over six months, with previous reports indicating significant slowing of disease progression and favorable safety outcomes.
NeuroSense is actively engaging with regulatory authorities to further advance PrimeC in hopes of gaining marketing authorization. This innovative treatment, a combined formulation of two existing FDA-approved drugs, targets critical mechanisms involved in ALS and aims to address the substantial unmet medical needs faced by ALS patients, whose numbers are projected to increase by 24% by 2040.
MWN-AI** Analysis
In light of the recently revealed long-term survival data from NeuroSense Therapeutics Ltd. that will be presented at a leading ALS scientific conference, investors should closely monitor the implications of these results for both NeuroSense and the broader biotechnology sector focused on neurodegenerative diseases.
The Phase 2b PARADIGM trial findings demonstrate a statistically significant 65% reduction in risk of death attributable to PrimeC, with an impressive median survival benefit of more than 14 months. These outcomes not only highlight the potential efficacy of PrimeC in treating ALS but also reinforce NeuroSense's position in a niche market that carries considerable unmet medical need. Investors should note that the favorable safety profile reported enhances the drug's profile and may bolster investor confidence as the company progresses into Phase 3 clinical trials.
As ALS afflicts over 5,000 individuals annually in the U.S. alone, the growing patient population could represent a lucrative market for effective therapies like PrimeC. Given that NeuroSense is actively engaging with regulatory authorities to move towards marketing authorization, a successful trajectory could lead to significant returns for investors.
Moreover, the favorable long-term data may catalyze increased interest and investment in NeuroSense, potentially increasing its stock value. However, given the inherent risks associated with clinical trials and biotechnology investments—particularly with forward-looking statements of potential timelines and outcomes—it is prudent for investors to weigh both the promising data and the uncertainties outlined in NeuroSense's filings with the SEC.
In conclusion, while the long-term survival data presents an encouraging narrative for NeuroSense, it is critical for investors to remain vigilant and informed regarding upcoming regulatory decisions, market competition, and the overall landscape of ALS therapies.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PR Newswire
CAMBRIDGE, Mass., March 9, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today announced that the recently reported long-term survival data from its Phase 2b PARADIGM trial of PrimeC in amyotrophic lateral sclerosis (ALS) will be presented at a leading scientific conference on March 9, 2026.
The survival analysis using a Cox proportional hazards model demonstrated benefit for PrimeC with a statistically significant 65% reduction in risk of death (hazard ratio: 0.35; p=0.0037) after adjusting for baseline risk factors and a greater than 14-month median survival benefit, calculated from the date of randomization (36.3 months vs. 21.4 months; log-rank p=0.0218) according to Kaplan–Meier survival estimates. The data will be presented at The Muscular Dystrophy Association (MDA) Clinical & Scientific Conference (March 9, 2026) during the 'Advancing ALS Therapeutics: Targets, Tools, and Trial Readiness' session.
The data will be presented by Dr. Jinsy Andrews, a recognized leader in ALS clinical research and a member of NeuroSense Scientific Advisory Board (SAB).
"These long-term survival findings from the Phase 2b randomized ALS study, PARADIGM, represent compelling evidence of a survival benefits," said Dr. Jinsy Andrews. "The favorable safety profile, the long-term survival data, together with recent findings showing that PrimeC regulates iron metabolism and miRNA in ALS, supporting target engagement, strongly reinforce the continued development of PrimeC in ALS. I look forward to sharing these data with the broader scientific community."
The PARADIGM Phase 2b trial was a randomized, double-blind, placebo-controlled study evaluating PrimeC in 68 people living with ALS. Participants were randomized 2:1 to receive PrimeC or placebo during the six-month double-blind period, followed by an open-label extension phase. Baseline characteristics were well-balanced between the two groups. Previously reported results demonstrated statistically significant slowing of disease progression, along with favorable safety and tolerability over 18 months of treatment.
The newly analyzed long-term survival data further strengthen the overall clinical dataset supporting PrimeC and provide additional context as NeuroSense advances regulatory engagement and preparations for the Phase 3 study.
NeuroSense continues active engagement with regulatory authorities to advance PrimeC toward potential marketing authorization.
About NeuroSense
NeuroSense Therapeutics, Ltd. is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. NeuroSense believes that these diseases, which include amyotrophic lateral sclerosis (ALS), Alzheimer's disease and Parkinson's disease, among others, represent one of the most significant unmet medical needs of our time, with limited effective therapeutic options available for patients to date. Due to the complexity of neurodegenerative diseases and based on strong scientific research on a large panel of related biomarkers, NeuroSense's strategy is to develop combined therapies targeting multiple pathways associated with these diseases.
For additional information, we invite you to visit our website and follow us on LinkedIn, YouTube and X. Information that may be important to investors may be routinely posted on our website and these social media channels.
About PrimeC
PrimeC, NeuroSense's lead drug candidate, is a novel extended-release oral formulation composed of a unique fixed-dose combination of two FDA-approved drugs: ciprofloxacin and celecoxib. PrimeC is designed to synergistically target several key mechanisms of ALS and AD, that contribute to neuron degeneration, inflammation, iron accumulation and impaired ribonucleic acid ("RNA") regulation to potentially inhibit the progression of ALS and AD.
About ALS
Amyotrophic lateral sclerosis ("ALS") is an incurable neurodegenerative disease that causes complete paralysis and death within 2-5 years from diagnosis. Every year, more than 5,000 people are diagnosed with ALS in the U.S. alone, with an annual disease burden of $1 billion. The number of people living with ALS is expected to grow by 24% by 2040 in the U.S. and EU.
Forward-Looking Statements
This press release contains "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will" "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on NeuroSense Therapeutics' current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict and include statements regarding the timing of regulatory filings, meetings and regulatory decisions. Further, certain forward-looking statements, including statements regarding future development of PrimeC, are based on assumptions as to future events that may not prove to be accurate. The future events and trends may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward looking statements. These risks include the uncertainty regarding outcomes and the timing of current and future clinical trials; the risk the PrimeC will not advance towards later-stage development, timing for reporting data, including from the study of PrimeC in Alzheimer's disease; that the study will not be successful; the ability of NeuroSense to remain listed on Nasdaq; and other risks and uncertainties set forth in NeuroSense's filings with the Securities and Exchange Commission (SEC). You should not rely on these statements as representing our views in the future. More information about the risks and uncertainties affecting NeuroSense is contained under the heading "Risk Factors" in the Annual Report on Form 20-F filed with the Securities and Exchange Commission on April 7, 2025 and NeuroSense's subsequent filings with the SEC. Forward-looking statements contained in this announcement are made as of this date, and NeuroSense undertakes no duty to update such information except as required under applicable law.
Logo: https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg
SOURCE NeuroSense
FAQ**
What specific mechanisms of action does PrimeC utilize to achieve the reported 65% reduction in risk of death, and how might this impact the future potential of NeuroSense Therapeutics Ltd. Warrant NRSNW as a viable investment?
How will the results from the Phase PARADIGM trial influence NeuroSense Therapeutics Ltd.'s strategy for the upcoming Phase 3 study, and what implications does this have for investors in NRSNW?
Can you elaborate on the favorable safety profile observed during the trial, and how this data might affect the market perception and valuation of NeuroSense Therapeutics Ltd. Warrant NRSNW moving forward?
Given the promising long-term survival data, what are the expected timelines for regulatory engagement and potential marketing authorization for PrimeC, and how could this timing impact the performance of NeuroSense Therapeutics Ltd. Warrant NRSNW?
**MWN-AI FAQ is based on asking OpenAI questions about NeuroSense Therapeutics Ltd. Warrant (NASDAQ: NRSNW).
NASDAQ: NRSNW
NRSNW Trading
0.0% G/L:
$0.208 Last:
101 Volume:
$0.208 Open:
